Ani Pharmaceuticals (ANIP) EBIT Margin (2011 - 2026)
Ani Pharmaceuticals (ANIP) reported EBIT Margin of 16.38% for Q1 2026, up 309.0% on a YoY basis from 4.0% in Q1 2025, and up 16.37% sequentially from 14.07% in Q4 2025.
Ani Pharmaceuticals (ANIP) EBIT Margin (2011 - 2026) Analysis & Trends
Ani Pharmaceuticals (ANIP) has 16 years of EBIT Margin data on file, last reported at 16.38% in Q1 2026.
- For the quarter ending Q1 2026, EBIT Margin rose 309.0% year-over-year to 16.38%; the trailing twelve-month figure through Mar 2026 stood at 13.4% (up 1244.0% YoY), and the FY2025 full-year result was 12.58%, up 1248.0% from the prior year.
- EBIT Margin advanced to 16.38% in Q1 2026, from 14.07% in the prior quarter.
- In the past five years, EBIT Margin ranged from a high of 16.38% in Q1 2026 to a low of 29.77% in Q1 2022.
- A 5-year average of 3.29% and a median of 6.57% in 2025 frame the typical range for EBIT Margin.
- Peak annual rise in EBIT Margin reached 4087 bps in 2022, while the deepest fall reached 5696 bps in 2022.
- Tracing ANIP's EBIT Margin over 5 years: stood at 1.93% in 2022, then jumped by 165 bps to 5.11% in 2023, then slumped by 145 bps to 2.3% in 2024, then surged by 713 bps to 14.07% in 2025, then climbed by 16 bps to 16.38% in 2026.
- Business Quant data shows ANIP's EBIT Margin at 16.38% in Q1 2026, 14.07% in Q4 2025, and 15.91% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 16.37% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 36.83% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -38.02% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 41.69% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -2.27% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 23.74% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 21.23% |
| 10 | Ani Pharmaceuticals | 1.64 Bn | 1.33 Bn | 143.88 Mn | 16.38% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 16.38% |
| Dec 31, 2025 | 14.07% |
| Sep 30, 2025 | 15.91% |
| Jun 30, 2025 | 6.57% |
| Mar 31, 2025 | 13.29% |
| Dec 31, 2024 | -2.30% |
| Sep 30, 2024 | -13.83% |
| Jun 30, 2024 | 3.74% |
| Mar 31, 2024 | 14.78% |
| Dec 31, 2023 | 5.11% |
| Sep 30, 2023 | 13.61% |
| Jun 30, 2023 | 10.64% |
| Mar 31, 2023 | 9.27% |
| Dec 31, 2022 | 1.93% |
| Sep 30, 2022 | -5.96% |
| Jun 30, 2022 | -17.48% |
| Mar 31, 2022 | -29.77% |
| Dec 31, 2021 | -38.94% |
| Sep 30, 2021 | -6.84% |
| Jun 30, 2021 | -31.99% |